Branford, CT – According to filings with the U.S. Securities and Exchange Commission, IsoPlexis is raising $85,000,061.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sean Mackay played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IsoPlexis

The future of advanced medicines relies upon deeper access to in vivo biology to create durable, curative impacts on disease. Our systems, which drive convergence of dynamic proteomics and single cell biology for the first time, are creating this deeper connection to accelerate curative medicines. IsoPlexis is dedicated to accelerating the fight against cancer and a range of our toughest diseases by producing the world’s most precise, award-winning detection systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise & personalized stage.

To learn more about IsoPlexis, visit http://www.isoplexis.com/

Contact:
Sean Mackay, Chief Executive Officer
475-221-8402
sean@isoplexis.com
https://www.linkedin.com/in/sean-mackay-0288a511/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved